Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00294931

Enrollment

Registered

2006-02-22

Start date

2006-02-28

Completion date

2009-01-31

Last updated

2010-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Small Cell Lung

Keywords

Lung Cancer, Small Cell, Extensive

Brief summary

This multicenter phase II trial is designed to study the unique combination of chemotherapy (irinotecan./carboplatin) and bevacizumab in the extensive-stage setting. This clinical setting seems ideal for evaluation of the role of bevacizumab in delaying progression and prolonging survival.

Detailed description

Eligible patients will receive 6 courses of irinotecan, carboplatin, and bevacizumab. The interval between chemotherapy courses will be 28 days. If after 6 courses of treatment, patient's response is a CR/PR/SD they will continue on Bevacizumab until tumor progression or up to 6 cycles (6 months) total. Treatment sequence: * Irinotecan 60mg/m2 on days 1, 8, and 15 * Carboplatin AUC=4 day 1 only * Bevacizumab 10 mg/kg days 1 and 15

Interventions

DRUGirinotecan

DRUGcarboplatin

DRUGbevacizumab

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologically confirmed small cell lung cancer,extensive stage disease. * Measurable or evaluable disease * No previous chemotherapy * Able to perform activities of daily living with minimal assistance * Adequate hematological, live and kidney function * Provide written informed consent

Exclusion criteria

* Limited stage disease * PEG or G tubes * Hemoptysis * Abdominal fistula, perforation, or abscess within the previous 6 months * Women who are pregnant or lactating * Proteinuria * Serious nonhealing wound, ulcer, or bone fracture * Evidence of bleeding diathesis or coagulopathy * Uncontrolled or serious cardiovascular disease * Uncontrolled brain metastasis * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days; Fine needle aspiration within 7 days * Patients requiring full-dose anticoagulation must be on a stable dosing schedule prior to enrollment

Design outcomes

Primary

Measure	Time frame
median time to progression	—

Secondary

Measure	Time frame
overall toxicity	—
overall response rate	—
duration of response	—
overall survival	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026